(Reuters) – AstraZeneca Plc’s Imfinzi has been approved in the European Union for previously untreated adult patients with extensive-stage small cell lung cancer (ES-SCLC), the drugmaker said on Tuesday.
The approval by the European Commission was based on positive results from a late-stage study in which Imfinzi plus chemotherapy showed a statistically significant improvement in overall survival of patients with ES-SCLC, AstraZeneca said.
(Reporting by Aakash Jagadeesh Babu in Bengaluru)
